Core Insights - In Q3 2025, the company reported total revenue of 7.425 billion yuan and a net profit attributable to shareholders of 924 million yuan, with net cash inflow from operating activities amounting to 1.107 billion yuan [1] Financial Performance - The company's latest debt-to-asset ratio stands at 53.79%, which is an increase of 0.13 percentage points from the previous quarter and an increase of 3.98 percentage points year-on-year [3] - The latest gross profit margin is 23.70%, reflecting a decrease of 0.53 percentage points from the previous quarter [3] - The return on equity (ROE) is reported at 5.09% [3] - The diluted earnings per share (EPS) is 1.45 yuan [3] - The total asset turnover ratio is 0.20 times, a decrease of 0.03 times compared to the same period last year, representing a year-on-year decline of 14.66% [3] - The inventory turnover ratio is 4.44 times, down 0.12 times year-on-year, which is a decline of 2.63% [3] Shareholder Structure - The number of shareholders is 47,300, with the top ten shareholders holding a total of 288 million shares, accounting for 43.98% of the total share capital [4] - The largest shareholder is Liu Fangyi, holding 35.3 million shares [4] - Other significant shareholders include various investment funds and banks, with holdings ranging from 0.46 million to 1.95 million shares [4]

智通财经APP讯，英科医疗(300677.SZ)发布2025年三季度报告，该公司前三季度营业收入为74.25亿 元，同比增长4.60%。归属于上市公司股东的净利润为9.24亿元，同比增长34.47%。归属于上市公司股 东的扣除非经常性损益的净利润为4.84亿元。基本每股收益为1.45元。 ...

Group 1 - The core viewpoint of the article highlights the financial performance of Yingke Medical for the third quarter of 2023, showing a revenue increase and significant growth in net profit and earnings per share [1] Group 2 - Yingke Medical reported approximately 7.425 billion yuan in revenue for the first three quarters of 2025, representing a year-on-year increase of 4.6% [1] - The net profit attributable to shareholders of the listed company was approximately 924 million yuan, reflecting a year-on-year increase of 34.47% [1] - The basic earnings per share reached 1.45 yuan, which is a year-on-year increase of 38.1% [1] - As of the report date, Yingke Medical's market capitalization stood at 27.6 billion yuan [1]

为使投资者全面了解报告期内公司的经营情况和财务状况，公司 《2025 年第三季度报告》将于 2025 年 10 月 28 日在巨潮资讯网 （www.cninfo.com.cn）披露，敬请投资者注意查阅。 证券代码：300677 证券简称：英科医疗 公告编号：2025-147 英科医疗科技股份有限公司 2025 年第三季度报告披露提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 10 月 27 日召开第四届董事会第十二次会议，审议通过了《关于<2025 年第三季度报告>的议案》。 特此公告。 英科医疗科技股份有限公司 董 事 会 2025 年 10 月 28 日 ...

英科医疗科技股份有限公司 2025 年第三季度报告 证券代码：300677 证券简称：英科医疗 公告编号：2025-148 英科医疗科技股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同 | 年初至报告期末 年初至报告期末 | | | --- | --- | --- | --- | --- | | | | 期增减 | 比上年同期增减 | | | 营业收入（元） | 2,511,275,781.81 | -2.90% | 7,424,714,825.22 | 4.60% | | 归属于上市公司股东的净利润 （元） | 213,970,729.66 | 113.04% | 924,410,713.59 | 34.47% | | 归属于上市公司股东的扣除非经 常性损益的净利润（元） | 84,280,208.92 | -25.87% | 484,481,437.92 | -19.32% | | ...

Group 1 - The core viewpoint of the news is that Yingke Medical's stock has increased by 5.01%, reaching a price of 42.13 CNY per share, with a trading volume of 565 million CNY and a turnover rate of 2.95%, resulting in a total market capitalization of 27.586 billion CNY [1] - Yingke Medical Technology Co., Ltd. is located in Zibo City, Shandong Province, and was established on July 20, 2009, with its listing date on July 21, 2017. The company operates in three main business segments: personal protection, rehabilitation care, and other products [1] - The revenue composition of Yingke Medical is as follows: personal protection accounts for 91.47%, rehabilitation care for 4.75%, and other products for 3.77% [1] Group 2 - From the perspective of the top ten circulating shareholders, a fund under Southern Fund ranks among the top shareholders of Yingke Medical. The Southern CSI 500 ETF (510500) increased its holdings by 967,200 shares in the second quarter, bringing its total to 6.698 million shares, which represents 1.43% of the circulating shares [2] - The estimated floating profit for the Southern CSI 500 ETF today is approximately 13.4629 million CNY [2] - The Southern CSI 500 ETF was established on February 6, 2013, with a latest scale of 113.438 billion CNY. Year-to-date returns are 28.62%, ranking 1823 out of 4219 in its category, while the one-year return is 28.52%, ranking 1678 out of 3877 [2]

证券日报网讯 10月24日晚间，英科医疗发布公告称，公司于近日接到公司控股股东刘方毅先生的通 知，获悉刘方毅先生将其所持有的公司部分股份办理了质押解除手续，解除质押股数为1，280，000 股。 （文章来源：证券日报） ...

Core Viewpoint - Inke Medical announced a significant investment of $70 million (approximately 500 million RMB) in Warburg Pincus Global Growth 15, L.P., aiming to enhance capital efficiency and financial returns while promoting deep integration of capital and industry [1][3]. Investment Details - The partnership fund has a target fundraising size of $17 billion, with Inke Medical participating as a limited partner (LP) [1][3]. - The fund's investment focus includes healthcare, energy transition, business services, industrial, technology, consumer sectors, and sustainable development [3]. Financial Performance - In the first half of 2025, Inke Medical reported revenue of 4.913 billion RMB, an increase of 8.9% year-on-year [3]. - The net profit attributable to shareholders was 710 million RMB, reflecting a year-on-year growth of 21.02% [3]. - The net cash flow from operating activities reached 745 million RMB, a significant increase of 170.15% compared to the same period last year [3]. - As of June 30, 2025, the total assets amounted to 39.515 billion RMB, up 14.10% from the end of the previous year [3]. - The cash and cash equivalents balance was 11.738 billion RMB, with trading financial assets totaling 10.857 billion RMB, bringing the combined total to 22.595 billion RMB [3]. Company Overview - Inke Medical Technology Co., Ltd. is a high-tech manufacturing enterprise focused on the research, production, and marketing of medical device consumables [3]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in July 2017 and offers a range of products including medical consumables, health care devices, and therapeutic care products [3].

Group 1 - The core point of the news is that Yingke Medical (SZ 300677) announced that as of the announcement date, Liu Fangyi has pledged a total of 29.87 million shares, accounting for 12.89% of his total holdings [1] - Yingke Medical's revenue composition for the year 2024 is entirely from medical devices, with a 100.0% share [2] - As of the time of reporting, Yingke Medical has a market capitalization of 26.3 billion yuan [3]

关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于近日接到公 司控股股东刘方毅先生的通知，获悉刘方毅先生将其所持有的公司部 分股份办理了质押解除手续。现将具体内容公告如下： 注：本公告总股本数以截至 2025 年 10 月 23 日公司最新总股本 654,793,743 股为计算标 准。 二、股东股份累计质押的情况 截至本公告披露日，刘方毅先生所持股份累计质押情况如下： 证券代码：300677 证券简称：英科医疗 公告编号：2025-146 英科医疗科技股份有限公司 三、其他说明 控股股东刘方毅先生资信状况良好，具备良好的资金偿还能力， 本次解除质押后，其剩余质押股份不存在实质性资金偿还风险，所质 押的股份目前不存在平仓风险或被强制过户的情形，质押风险可控， 不会对公司生产经营、公司治理等产生影响。公司将持续关注其质押 情况及质押风险情况，并按规定及时做好相关信息披露工作，敬请投 资者注意投资风险。 四、备查文件 1、中国证券登记结算有限责任公司深圳分公司证券质押及司法 冻结明细表； 2 ...